HC Wainwright Analysts Lower Earnings Estimates for PDSB

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Analysts at HC Wainwright reduced their Q2 2025 earnings estimates for PDS Biotechnology in a research note issued to investors on Wednesday, June 11th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.25) per share for the quarter, down from their previous estimate of ($0.22). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology's Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($0.92) EPS.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04.

Separately, Wall Street Zen downgraded shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday.

PDS Biotechnology Stock Up 1.7%

Shares of PDS Biotechnology stock traded up $0.03 during trading on Friday, hitting $1.78. 288,563 shares of the stock traded hands, compared to its average volume of 494,283. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The stock's fifty day simple moving average is $1.36 and its 200 day simple moving average is $1.46. The firm has a market cap of $81.36 million, a P/E ratio of -1.53 and a beta of 1.27. PDS Biotechnology has a 52-week low of $0.85 and a 52-week high of $4.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in PDS Biotechnology during the fourth quarter valued at about $58,000. Two Sigma Investments LP lifted its position in shares of PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock valued at $107,000 after buying an additional 48,132 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of PDS Biotechnology during the fourth quarter valued at about $26,000. Blair William & Co. IL boosted its holdings in shares of PDS Biotechnology by 29.4% in the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock valued at $257,000 after buying an additional 35,757 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of PDS Biotechnology in the 4th quarter worth approximately $89,000. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.